Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Results of an early analysis of a phase II clinical trial presented at the 2012 San Antonio Breast Cancer Symposium show that combining the aromatase inhibitor letrozole with the study medicine PD-0332991 increased median progression-free survival by 18.6 months compared to taking letrozole alone.
NEW YORK (Reuters Health) - A new review of existing evidence suggests that using magnetic resonance imaging to "stage" a woman's breast cancer before surgery might do more harm than good.
The U.S. Supreme Court on Friday agreed to decide whether human genes can be patented, a hotly contested issue with broad consequences for the future of gene-based medicine.
NEW YORK (Reuters Health) - More than one in five women with early-stage breast cancer in a new study said they were given too much responsibility for treatment-related decisions - and those patients were more likely to end up regretting the choices they made.
CHICAGO (Reuters) - Controversial U.S. guidelines for mammography issued in 2009, calling for screening every two years rather than annually for women over 50 years old, can result in breast cancers being missed, according to U.S. researchers studying the hotly debated topic.
NEW YORK (Reuters Health) - A new study ties advertising for breast cancer drugs known as aromatase inhibitors to a slight increase in the total number of prescriptions for those medications.
NEW YORK (Reuters Health) - Women with a new diagnosis of breast cancer who are covered by Medicare are waiting longer and longer to get treatment, according to a new nationwide study.
NEW YORK (Reuters Health) - People who have been treated for cancer often have lingering fatigue, but a new analysis of more than three dozen studies suggests regular walking or cycling might help boost their energy.
Women with breast cancer may experience problems with tasks like finding the right words to convey a message or following directions to a destination more than six months after chemotherapy treatment ends, a recent analysis finds. While these verbal and visuospatial issues may be concerning, no other cognitive functions, such as attention, focus, memory or dexterity, were significantly affected after treatment ended.
A re-analysis of data from the NeoALTTO trial found that women whose tumors disappeared after neoadjuvant, or pre-surgery, treatment, were just as likely to have mastectomy as they were to have lumpectomy.